Equibles does not estimate personal net worth.
Get an email with a short summary when Amphastar Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AMPH alertsBill Peters is recorded as CFO at Amphastar Pharmaceuticals, Inc. (AMPH). Bill Peters has spoken on 14 earnings calls and 2 other investor events across 1 company, most recently for Amphastar Pharmaceuticals, Inc. on November 5, 2026. Amphastar Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Amphastar Pharmaceuticals, Inc. includes Jack Yongfeng Zhang (CEO and Board Member), William J. Peters (CFO and Board Member), William Peters (CFO) and 7 others.
“In my comments today, I will discuss the third quarter results and then update some of our assumptions for 2026. Revenues for the third quarter increased 8% to $207.6 million, which is the highest amount we have ever recorded in one quarter.”
“In my comments today, I will discuss the second quarter results and then update some of our assumptions for 2026. Revenues for the second quarter increased 5% to $183.9 million from $174.4 million in the previous year's period.”
“So obviously we are not sure if they are going to launch or not launch the authorized generic, but as we move further away from our launch, which is mid-April, and from our approval, which is in February, the further away we are from that date, the least likely they will launch an authorized generic.”
“As we mentioned on our conference call, that's something where people are buying the drug at the mandated lowest price for the 340B hospitals and then still collecting a rebate when they issue it to someone who has insurance coverage.”
“Revenues for Q3 increased 6% to $191.2 million from $180.6 million in the previous year's period. BAQSIMI sales through Amphastar totaled $40.4 million in Q3.”
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
